Biopsin

Singapore, Singapore Founded: 2018 • Age: 8 yrs
Real-time microbial detection system is developed for product testing.
Request Access

About Biopsin

Biopsin is a company based in Singapore (Singapore) founded in 2018 by Amit Kumar and Sheetal Sinha.. Biopsin has raised $175 thousand across 1 funding round from investors including HAX and Entrepreneur First. Biopsin operates in a competitive market with competitors including AFYREN, Spore Biotechnologies, Mesosil, Celsis and Source Molecular, among others.

  • Headquarter Singapore, Singapore
  • Founders Amit Kumar, Sheetal Sinha
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biopsin Pte Ltd
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $175 K (USD)

    in 1 rounds

  • Latest Funding Round
    $175 K (USD), Seed

    Jan 23, 2019

  • Investors
    HAX

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Biopsin

Biopsin has successfully raised a total of $175K through 1 strategic funding round. The most recent funding activity was a Seed round of $175 thousand completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $175,000
  • First Round

    (23 Jan 2019)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2019 Amount Seed - Biopsin Valuation HAX , Entrepreneur First
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biopsin

Biopsin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include HAX and Entrepreneur First. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Startups are accelerated via a 111-day program with seed funding.
Founded Year Domain Location
Provider of a program turning individuals into funded technology company founders
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biopsin

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Biopsin

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biopsin Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biopsin

Biopsin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AFYREN, Spore Biotechnologies, Mesosil, Celsis and Source Molecular, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
domain founded_year HQ Location
Microbial detection technology is developed for life science industries.
domain founded_year HQ Location
Antimicrobial materials are developed for infection prevention in medical devices.
domain founded_year HQ Location
Rapid microbial screening systems are manufactured for quality control testing.
domain founded_year HQ Location
Technology for microbial source tracking is provided by Source Molecular.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biopsin

Frequently Asked Questions about Biopsin

When was Biopsin founded?

Biopsin was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Biopsin located?

Biopsin is headquartered in Singapore, Singapore.

Who is the current CEO of Biopsin?

Amit Kumar is the current CEO of Biopsin. They have also founded this company.

Is Biopsin a funded company?

Biopsin is a funded company, having raised a total of $175K across 1 funding round to date. The company's 1st funding round was a Seed of $175K, raised on Jan 23, 2019.

What does Biopsin do?

Biopsin was founded in 2018 in Singapore and operates in the biotechnology sector. A microbial detection system is provided for analyzing food, beverages, water, consumer goods, and pharmaceuticals. Pathogenic microbes are extracted and trapped from samples, followed by quantitative analysis at the single-cell level. Operations are focused on real-time testing to ensure product safety across these industries.

Who are the top competitors of Biopsin?

Biopsin's top competitors include AFYREN, Spore Biotechnologies and NCIMB.

Who are Biopsin's investors?

Biopsin has 2 investors. Key investors include HAX, and Entrepreneur First.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available